CRP and COVID-19: In addition, we evaluate the removal of hyperinflammatory parameters with the ATA membrane in MHD patients with COVID-19, through a variety of biomarkers of systemic inflammation (neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-lymphocyte (MLR) lymphocyte-to-C-reactive protein (LCR) ratios, and interleukin 6 (IL-6)).